NMPA GMP Inspection Requirements: What Manufacturers Need to Know
The National Medical Products Administration (NMPA) is China’s principal regulatory authority responsible for evaluating and enforcing Good Manufacturing Practice (GMP) compliance across the pharmaceutical sector. As China continues to integrate into global regulatory networks, its GMP inspections have become more aligned with international expectations—yet still retain unique procedural elements. This article outlines the essential GMP inspection requirements of the NMPA, highlighting preparation, compliance expectations, and licensing consequences for pharmaceutical manufacturers.
NMPA’s Legal Framework and Regulatory Scope
- GMP enforcement is governed by:
- Drug Administration Law of the PRC (Amended 2019)
- Measures for the Supervision and Administration of Drug Production
- Chinese GMP Standards (2010 Revised Edition), aligned with WHO and PIC/S guidance
- Regulatory oversight includes:
- Drug manufacturing facilities (APIs and FDFs)
- Contract manufacturers and importers
- Pharmaceutical storage, transportation, and stability testing
Types of GMP Inspections Conducted by NMPA
- Initial GMP Inspections: Required for licensing new manufacturing or packaging sites
- Routine Surveillance Inspections: Performed every 2–3 years or based on risk assessment
- For-Cause Inspections: Initiated by complaints, regulatory findings, or public safety concerns
- Follow-Up Inspections: Verify closure of corrective actions for prior deficiencies
- Overseas GMP Inspections: Target manufacturers supplying the Chinese market
Inspection Planning and Execution Process
- NMPA announces audit schedule or performs surprise inspection
- Inspectors
conduct on-site walkthroughs, process observation, and system review
Areas of focus:
Closing meeting with preliminary findings and compliance expectations
Issuance of written inspection report and deficiency notice
- Quality Management System (QMS)
- Document control and SOP implementation
- Personnel qualification and training
- Batch manufacturing and packaging records
- Environmental monitoring and equipment validation
- Audit trail and data integrity in electronic systems
NMPA Deficiency Classification System
- Observations categorized as:
- Critical: Severe risk to patient safety or intentional GMP violation
- Major: Systemic GMP weakness potentially affecting product quality
- Minor: Procedural or documentation lapses without direct product risk
- Critical deficiencies often result in:
- License suspension or product registration rejection
- Recalls and import bans
- Administrative penalties and public notification
CAPA Expectations After NMPA Inspections
- Companies must respond within 30 working days with a full CAPA plan
- CAPA response must include:
- Root cause analysis
- Immediate containment actions
- Long-term preventive measures
- Timeline for completion and evidence of implementation
- CAPA closure may be verified via re-inspection or documentary review
- Failure to close deficiencies may affect renewal of production license or product listing
Key Focus Areas in Recent NMPA Audits
- Electronic recordkeeping without secured access controls
- Inadequate cleaning validation for shared manufacturing equipment
- Incomplete training records and expired competency assessments
- Missing justification for shelf-life and expiry assignments
- Inconsistent batch reconciliation and raw material traceability
Inspection Requirements for Overseas Manufacturers
- Foreign firms must submit a GMP Compliance Dossier when applying for registration
- NMPA may initiate an overseas inspection based on:
- Product risk level (injectables, biologics, etc.)
- Past non-compliance history
- Volume of imports into China
- On-site inspections are coordinated through international regulatory liaison offices
- Mutual reliance may be accepted with selected PIC/S or ICH member jurisdictions
GMP Licensing and Certification
- After passing inspection, companies receive:
- GMP Certificate (valid for 5 years, renewable)
- Manufacturing License (Production Permit)
- License updates required for:
- Facility expansion or site change
- Introduction of new dosage forms
- Transfer of ownership or management
Digitalization and Data Integrity Oversight
- NMPA mandates:
- Electronic systems must have audit trails and controlled access
- System validations and backup procedures
- Data review practices compliant with ALCOA+ principles
- Non-compliance in data handling frequently results in Major or Critical findings
- Expectations apply equally to domestic and foreign facilities
Best Practices for NMPA Inspection Readiness
- Ensure complete alignment with China GMP 2010 (Revised)
- Maintain Chinese-language Site Master File and all critical GMP records
- Track training logs, batch records, and validation reports with audit-ready precision
- Simulate inspections using NMPA-published enforcement reports and deficiency databases
- Coordinate with a local regulatory agent for ongoing compliance updates
Conclusion
With China representing one of the largest and most dynamic pharmaceutical markets in the world, compliance with NMPA GMP inspection requirements is essential for domestic and global manufacturers alike. By adhering to NMPA’s risk-based inspection model, data integrity expectations, and documentation standards, companies can strengthen their market access and reputation while aligning with the highest quality assurance frameworks globally.